


REMARKS

Currently claims 1-7 are pending. Applicants have attached an abstract on a separate sheet of paper as required by US practice, and have amended the specification for purposes of adding the priority information.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,



Michael M. Conger
Attorney for Applicants
Registration No. 43,562

Date: September 3, 2004
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-2474
Facsimile: 919-483-7988